Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multimeric-001
- Development stage
- Discontinued
- Lead developer
- Scinai Immunotherapeutics
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Administration
- Intramuscular
01
Overview
Multimeric-001 (M-001) is a synthetic peptide-based universal influenza vaccine candidate. It consists of three copies each of nine conserved linear epitopes derived from the hemagglutinin (HA), nucleoprotein (NP), and matrix 1 (M1) proteins of influenza A and B viruses. These epitopes are designed to induce both humoral and cellular immune responses, activating CD4+ and CD8+ T cells as well as antibody production against a broad range of influenza strains. The vaccine is administered intramuscularly as a suspension for injection. Developed originally by BiondVax Pharmaceuticals, now known as Scinai Immunotherapeutics, Multimeric-001 has been evaluated in multiple clinical trials for its ability to prime immune responses to seasonal influenza vaccines in adults and the elderly. As a standalone vaccine, it induces significant cell-mediated immunity but does not generate hemagglutinin inhibition antibodies on its own[1][2][3][6].
- Other names
- M 001M001M-001
02
Targets
Influenza matrix protein 1 conserved epitopesNP (Influenza virus nucleoprotein)MHC I (MHC class I})HA (Hemagglutinin)M1 (Muscarinic acetylcholine receptor M1)
Beyond the preview
Go deeper on multimeric-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multimeric-001.